US 11,793,755 B2
Pharmaceutical composition for intraarticular delivery
Keelung Hong, South San Francisco, CA (US); Luke S. S. Guo, South San Francisco, CA (US); Yun-Long Tseng, Taipei (TW); Sheue-Fang Shih, Taipei (TW); Po-Chun Chang, Taipei (TW); Chih-Chiang Tsai, Taipei (TW); and Hong-Hui Lin, Taipei (TW)
Assigned to TAIWAN LIPOSOME CO., LTD., Taipei (TW); and TLC BIOPHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed by TAIWAN LIPOSOME CO., LTD., Taipei (TW); and TLC BIOPHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed on Jan. 5, 2021, as Appl. No. 17/141,550.
Application 17/141,550 is a continuation of application No. 16/875,167, filed on May 15, 2020, granted, now 10,959,951.
Application 16/875,167 is a continuation of application No. 16/439,124, filed on Jun. 12, 2019, granted, now 10,736,846, issued on Aug. 11, 2020.
Application 16/439,124 is a continuation of application No. 15/695,649, filed on Sep. 5, 2017, granted, now 10,322,086, issued on Jun. 18, 2019.
Application 15/695,649 is a continuation of application No. 14/411,530, granted, now 9,789,062, issued on Oct. 17, 2017, previously published as PCT/US2013/049442, filed on Jul. 5, 2013.
Claims priority of provisional application 61/791,650, filed on Mar. 15, 2013.
Claims priority of provisional application 61/668,446, filed on Jul. 5, 2012.
Prior Publication US 2021/0145744 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 31/405 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/405 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 38/1793 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01); C07K 2319/30 (2013.01)] 21 Claims
 
1. A mixture for intraarticular delivery of a therapeutic agent, the mixture comprising:
a first phospholipid, a second phospholipid, and cholesterol, wherein the first phospholipid is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC), soy phosphatidylcholine (SPC), and egg phosphatidylcholine (EPC), and the second phospholipid is polyethyleneglycol distearoylphosphatidylethanolamine (PEG-DSPE) or dipalmitoylphosphatidylglycerol (DOPG); and
wherein the cholesterol is at a mole percent of about 10 to about 33 based on the total amount of the first phospholipid, the second phospholipid and cholesterol.